TIMEWELL
Solutions
Free ConsultationContact Us
TIMEWELL

Unleashing organizational potential with AI

ISO/IEC 27001 (ISMS) certification mark (SGS / ISMS-AC)

ISO/IEC 27001:2022 certified Certificate No. JP26/00000255 Scope: Planning, development and operation of SaaS products utilizing AI technology

Services

  • ZEROCK
  • TRAFEED
  • TIMEWELL BASE
  • WARP
  • WARP 1Day
  • WARP NEXT Corporate
  • WARP BASIC
  • WARP ENTRE
  • Alumni Salon
  • WARP for Schools
  • Alumni Ventures
  • FDE
  • AI Consulting
  • EMC GLOBAL

Company

  • About Us
  • Team
  • Why TIMEWELL
  • News
  • Contact
  • Free Consultation

Content

  • Insights
  • Knowledge Base
  • Case Studies
  • Whitepapers
  • Events
  • Solutions
  • AI Readiness Check
  • ROI Calculator

Legal

  • Privacy Policy
  • Manual Creator Extension
  • WARP Terms of Service
  • WARP NEXT School Rules
  • Legal Notice
  • Security
  • Anti-Social Policy
  • ZEROCK Terms of Service
  • TIMEWELL BASE Terms of Service

Newsletter

Get the latest AI and DX insights delivered weekly

Your email will only be used for newsletter delivery.

© 2026 株式会社TIMEWELL All rights reserved.

Contact Us
HomeTRAFEED MediaExport Control in Practice for Medical Device Makers | Where PMD Act Meets FEFTA, and 2026 Actions After Core-Sector Designation
TRAFEED Media

Export Control in Practice for Medical Device Makers | Where PMD Act Meets FEFTA, and 2026 Actions After Core-Sector Designation

Published2026-04-24Updated2026-11-22Ryuta Hamamoto
Export ControlMedical DevicesPMD ActFEFTAEconomic SecurityTRAFEED

Since the 2020 core-sector designation, medical device makers have had to run two layers of regulation — the PMD Act and FEFTA — at the same time.

Export Control in Practice for Medical Device Makers | Where PMD Act Meets FEFTA, and 2026 Actions After Core-Sector Designation
Share

(November 22, 2026) We had described shipping products or parts from the US to third countries as a "re-export." Under the EAR's definitions, sending an item out of the United States is an export, and a reexport is a shipment from one foreign country to another (15 CFR 734.13 and 734.14), so the text now says export. The description of who counts for a deemed export now follows the EAR's definition of a foreign person (anyone other than US citizens, permanent residents and other protected individuals; 15 CFR 772.1).

Hello, this is Hamamoto from TIMEWELL.

This is the second installment of the industry-specific series, and this time we are looking at medical device makers. Medical devices carry a "tools that save lives" image, and they rarely come up in export control discussions. But once you get into the operational side, the strict quality rules under the PMD Act sit on top of a separate regulatory axis called FEFTA — and from 2020 onward, core-sector designation and geopolitical risk were layered on top of that. Olympus holds roughly 70% global share in gastrointestinal endoscopy1, and Canon Medical ships into over 150 countries and regions2. Those are proud numbers, and they also mean that the blast radius when export control goes wrong is huge.

This piece walks through the concrete issues an export-control officer at a medical device maker faces in 2026, with my own view included. If your company still runs the PMD Act team and the export control team as separate departments, this is written for you.

Work through a medical-goods classification on a fill-in sheet: A checklist covering pharmaceuticals, medical devices, bio, pharma chemicals and nuclear medicine — from Japan's Appended Table 1 (chemical = Row 3, biological = Row 3-2, nuclear = Row 2) and the goods ordinance, through the Australia Group / CWC / BWC / NSG, to the US EAR (CCL Category 1, EAR99, the 744.4 catch-all) and ITAR (USML Cat XIV). Your regulatory-affairs and export-control people can work from the same sheet and keep the reasoning on record, so it serves both as the draft of your internal classification and as an explanation you can hand to a counterparty. It also builds in the point that EAR99 does not mean "no license needed." → Download the Medical Goods Classification Checklist (2026) (Free. Your company name and work email are required.)

What the 2020 core-sector designation really put on the table

On June 15, 2020, the Ministry of Finance, METI, and the Ministry of Health, Labour and Welfare jointly announced that two sectors related to pharmaceuticals and medical devices would be added to FEFTA's core sectors3. Precisely, the three categories were pharmaceuticals against pathogenic organisms, pharmaceutical intermediates, and manufacturing of high-risk medical devices. The rules took effect on July 15 of that year.

The core-sector designation itself is a net cast over inward direct investment, meaning "money coming in from abroad." Foreign entities or individuals acquiring 1% or more of a listed company's shares in the target sectors now need prior notification and review. That is a major step down from the previous 10% threshold — in practice, it puts every move by activists and funds in plain view.

The stated rationale was, in the wake of the COVID-19 pandemic, to maintain "a domestic manufacturing base for critical healthcare industries essential to citizens' lives and health." At the time, shortages of masks and ventilators had become a global political issue, and the move was emblematic of pulling the pandemic response into the economic-security frame.

The misread I want medical device makers to avoid is, "We are not listed, we have no foreign shareholders, so this does not concern us." The core-sector designation was the Japanese government's formal declaration that "this industry is tied directly to national security." Investment rules are only one face of it — on the back side, the same standards now apply to export-side management, supply-chain visibility, and counterparty due diligence. METI's Security Export Control Policy Division is, as I hear it, stepping up interviews and internal-control reviews in the medical device space. Five years on, the initial shock has faded, but the operational depth is, if anything, deeper than before.

Who closes the gap between the PMD Act and FEFTA?

The trickiest thing in medical device export control is that two laws with very different character — the PMD Act and FEFTA — apply to the same goods at the same time.

The PMD Act, formally the "Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices," is there to secure product quality and safety. FEFTA's export rules, in contrast, restrict the transfer of goods and technology to specific destinations, end users, or end uses on national-security grounds. Because the purposes differ, it is perfectly normal for a product that fully meets PMD Act requirements to be a "no-go" under FEFTA.

For example, when shipping a device whose name or packaging design has been changed for the destination market, the PMD Act side requires a "Notification of Manufacturer and Marketer of Export-Use Medical Device" and a medical-device manufacturing license4. A June 22, 2022 administrative notice from MHLW's Pharmaceutical Safety and Environmental Health Bureau revised the Q&A on this notification and organized how changes made to meet the destination country's rules should be handled5. In other words, the PMD Act side continues to be updated at a fine level of granularity.

For the same product, however, FEFTA demands an entirely separate analysis — which item of Annex 1 of the Export Trade Control Order it might fall under, and which destination, end user, or end use raises catch-all concerns. The classification record is checked by customs at the time of export, and the end-use undertaking is obtained by the exporter's own responsibility. JETRO's Q&A explicitly notes that medical devices are subject to catch-all controls and that self-declared classification documents must be submitted6.

Very few Japanese medical device makers have staff who bridge both laws. Regulatory affairs specialists know the PMD Act, export control specialists know FEFTA, and they usually sit in different departments producing different documents — only comparing notes when the same product happens to come up on both sides. In my own consulting work, I have repeatedly seen cases where the regulatory side says "our Class II device can be exported with no issue," the export-control side says "this destination is difficult," and the operations team is left stuck in the middle. This gap is not a rulemaking problem. It is an organizational design problem.

Replace siloed classification work with AI.

METI's FY2024 data shows 52% of foreign exchange law violations stem from classification errors. Download the TRAFEED product catalog covering features and rollout.

Download Product CatalogContact About TRAFEED

Olympus, Terumo, and Canon Medical all face the same two-layer wall

Among Japan's leading medical device makers — Olympus, Terumo, Canon Medical Systems, Nipro, Fukuda Denshi — overseas revenue is high, and the US and China together account for a large share of sales.

Olympus is said to hold about 70% global share in gastrointestinal endoscopy and has led the market for years1. And yet in its FY ending March 2026 operating-profit guidance, the company estimated a roughly 16 billion yen hit from US tariff policy, stating directly that a significant portion of GI endoscopes are manufactured in Japan and therefore exposed to tariffs7. Importing into the United States is not itself subject to the US Export Administration Regulations (EAR), but exporting products or parts from the US to third countries (an "export" under the EAR), or releasing technical information inside the US to employees who are foreign persons under the EAR (anyone other than US citizens, permanent residents and other protected individuals), does call for an EAR check. Repair flows, shipments to third countries, and part movements between local sales affiliates all need to fall inside your management reach.

Terumo, which makes a broad portfolio including catheters and syringes, has publicly said it is already producing a meaningful share of US-bound volume inside the United States. It is pursuing inventory management and price pass-through to soften the tariff impact, but the more you lift local production, the more a second set of risks appears — technology transfer, deemed export, and disclosure of technical information to locally hired engineers. Technology lives in people. Passing controlled technology from headquarters in Japan to a US site is itself a provision of technology under Japan's FEFTA (Article 25(1)) and needs a license where it is controlled. Releasing that technology inside the US to locally hired engineers who are foreign persons under the EAR (not US citizens, permanent residents or other protected individuals) also raises the EAR's deemed-export question. I have written a separate piece on this; see Deemed Export Risk Guide.

Canon Medical Systems covers CT, MRI, ultrasound, and X-ray systems across more than 150 countries and regions2. In 2024 the company announced a collaboration with Olympus on endoscopic ultrasound systems — a visible example of Japanese makers tying up to take on US rivals8. Diagnostic imaging equipment carries particularly high dual-use potential; it can be used inside nuclear facilities for internal inspection or inside military research institutions, so shipping CT- and MRI-class equipment to specific countries demands careful classification and end-use verification. ECCN (the US Export Control Classification Number system) is a useful lens even for Japan's classification. If you want the basics, our What Is an ECCN? Classification Basics is a good starting point.

Beyond these three companies, Japanese medical devices as a whole are often described in the press as "on the road to 21 trillion yen" — a huge market heavily dependent on the US, China, and Europe9. Beyond tariffs, a single export-control miscue that halts shipments can cost hundreds of millions of yen per year. Export control gets treated as a "defensive function," but in reality it sits on the revenue tap. That is how I see it.

The overlooked dual-use angle on Class II and III devices

Japan's device classification runs on its own risk tiers — Class I (general), Class II (controlled), Class III and IV (high-risk controlled). Core-sector designation largely targets Class III and above, but FEFTA risk does not line up with these classes.

Endoscopes are usually Class II, yet you cannot rule out a military medical facility, a facility disguised as a clinical trial site, or a classified military research lab as the real end user. Portable ultrasound is similar — it can be used in battlefield medicine, military field hospitals, or even as medical equipment inside submarines.

Diagnostic imaging adds harder questions. A CT scanner images cross-sections of the human body, but the same technology can perform non-destructive inspection of nuclear weapon parts or electronic components. MRI systems produce strong magnetic fields; their parts or underlying technology have been flagged for potential conversion into military sensors. Ventilators and anaesthesia machines — counterintuitive as it seems — have been discussed as risky inputs for facilities doing animal experiments for biological weapons.

These dual-use angles must be evaluated as a combination of destination and end user. An endoscope for a Chinese Class-A tertiary general hospital and the same model sent to an unnamed research institute in the same country require completely different levels of verification. On January 6, 2026, China's Ministry of Commerce issued a notice tightening export controls on dual-use items destined for Japan10. Controls are moving not just from Japan to China but also from China to Japan, so makers are starting to revisit procurement routes for repair parts and consumables.

I have organized the relationship between list controls and catch-all controls in separate pieces. For the big-picture regulatory architecture, read Export Compliance Program Guide and Japan-China Export Control 2026 first — everything flows more easily after that.

Three things medical device makers should revisit under 2026's geopolitics

Here is what I tell medical device makers: "If you only look at three things first, look at these." I am prioritizing rather than going for completeness.

First, upgrade classification from "per model number" to "per model number plus destination plus end user." Many companies classify a model once and reuse that record for years. That does not match a 2026 environment where FEFTA-controlled items are being added and revised frequently and destination risk scores are moving around. Russia-bound shipments in particular have, since March 2022, been effectively unapprovable by the METI minister11. Middle East destinations and circumvention through Southeast Asia have to be re-scored by destination on an ongoing basis.

Second, integrate decision-making between the regulatory affairs team and the export-control team. At the medical device makers I know, regulatory affairs sits against MHLW, export control sits against METI, and the two organizations are completely separate. You need a forum that bridges them, so that PMD Act and FEFTA requirements are discussed at the same table from the development stage. Companies that front-load launches in the US or Europe tend to get pulled toward FDA or CE work and leave FEFTA items to the back burner. That has to be consciously corrected.

Third, deploy automated screening against denial lists (sanctioned-party lists). Medical device customers span hospitals, medical corporations, distributors, and trading companies — multi-layered — and manually cross-checking all of them against OFAC, EU sanctions, and Japan's Foreign End User List does not scale. With China's dual-use rules taking effect in January 2026, some partners are starting to appear on the Chinese side's entity lists, so three-way screening across the US, China, and Japan is becoming the operational standard. For the counterparty-vetting mindset, see Deemed Export Risk Guide and past articles.

None of those three hold up if attempted by human effort alone. That is exactly where AI agents become a real option.

Also readDeemed Exports and the "Specified Categories" in 5 Minutes | Hiring, Secondments and Joint Research Risks After the 2022 AmendmentHow do you manage deemed exports in R&D settings?

AI as a way for the control manager to focus on judgment

My stance is that AI is "not a tool that replaces people," but "a mechanism that lets the control manager focus on judgment." Medical devices go directly to human lives, and the final decision must always rest with a human accountable manager. What AI can compress is the time-consuming work leading up to that decision — information gathering, document drafting, cross-checking, record-keeping.

A small export-control team facing 1,000+ SKUs and shipments to more than 150 countries — you cannot solve that with more rules. You solve it with the right mechanism. That is my conclusion.

If you want medical-device classification and counterparty screening to run as a routine process, you can contact us about TRAFEED. An overview of its features is in the TRAFEED service catalog (PDF).

References

Footnotes

  1. Diamond Online, "Canon, Fuji, Terumo, Olympus — Japanese medical device makers on the road to 21 trillion yen and how they plan to beat the US giants" https://diamond.jp/articles/-/356746 ↩ ↩2

  2. Olympus, "Canon Medical Systems and Olympus agree to collaborate on endoscopic ultrasound systems" https://www.olympus.co.jp/news/2024/nr02608.html ↩ ↩2

  3. Sustainable Japan, "[Japan] Government designates two pharmaceutical and medical device sectors as core sectors under revised FEFTA" https://sustainablejapan.jp/2020/06/18/japan-forex-act-2/50996 ↩

  4. Nishimura & Asahi, "Core-sector designation under FEFTA for manufacturing of pharmaceuticals and high-risk medical devices" https://www.amt-law.com/asset/pdf/bulletins1_pdf/200709.pdf ↩

  5. MHLW Pharmaceutical Safety and Environmental Health Bureau, Pharmaceutical Evaluation Division, "Revision of the Q&A on handling notifications for export-use pharmaceuticals and related products" (June 22, 2022 administrative notice) https://www.pmda.go.jp/files/000247110.pdf ↩

  6. JETRO, "Approval matters for pharmaceutical exports in Japan" https://www.jetro.go.jp/world/qa/04A-000925.html ↩

  7. Newswitch, "Olympus, Terumo — unavoidable US tariff impact on medical devices and each company's countermeasures" https://newswitch.jp/p/46746 ↩

  8. Toyo Keizai Online, "[Medical devices] Canon, Fujifilm, Olympus — Japanese makers on the global stage face a defining moment" https://toyokeizai.net/articles/-/892051 ↩

  9. JETRO, "Import procedures for medical devices: Japan" https://www.jetro.go.jp/world/qa/04M-010754.html ↩

  10. JETRO, "FY2026 NDAA enacted — expanded restrictions on Chinese biotech firms and US investment into China" https://www.jetro.go.jp/biznews/2025/12/28e03471e6967274.html ↩

  11. METI, "Exports to Russia and related destinations" https://www.meti.go.jp/policy/external_economy/trade_control/02_export/17_russia/russia.html ↩

This article was produced with the help of AI. A human verified the primary sources and edited the text before publication.

Read next

Articles that answer the question you are likely to have next.

  1. 1What Is Inward FDI Screening in Japan? A Plain-English Guide to FEFTA Prior Notification, the 1% Rule, and Core Sectors (2026)What does core-sector designation require when accepting foreign investment?
  2. 2Deemed Exports and the "Specified Categories" in 5 Minutes | Hiring, Secondments and Joint Research Risks After the 2022 AmendmentHow do you manage deemed exports in R&D settings?
  3. 3What Is an ECCN? How to Read the Code and Look Up Your Product's ECCN (2026)How do you look up a product's ECCN under the US EAR?

This article is part of TRAFEED Media, our practical media on export controls and economic security

Back to TRAFEED MediaThis week's regulatory updates

52% of FY2024 export-control violations stem from classification errors. Is your team covered?

METI FY2024 data shows over half of violations stem from classification. Start with a free 5-question light check (~2 min, no email), then continue to the full 10-question report.

Contact About TRAFEED
Contact About TRAFEEDContact form (about 3 min)TRAFEED product briefFeatures & rollout in PDF

Share this article if you found it useful

Share

Newsletter

Get the latest AI and DX insights delivered weekly

Your email will only be used for newsletter delivery.

Free download

Recommended materials

Medical Goods Classification Checklist (Pharma, Devices, Bio / Japan Table 1 Rows 3 & 3-2 etc. / AG, CWC, BWC, NSG / US EAR & ITAR, 2026)

A fill-in working sheet to classify pharmaceuticals, medical devices, bio, pharma chemicals and nuclear medicine — from Japan's Appended Table 1 (chemical = Row 3, biological = Row 3-2, nuclear = Row 2) and the goods ordinance, through the Australia Group / CWC / BWC / NSG, to the US EAR (CCL Category 1 / EAR99 / the 744.4 catch-all) and ITAR (USML Cat XIV). With a plain-language intro; built to reference the official control-list text rather than enumerate individual pathogens. Based on primary sources (e-Gov, AG, OPCW, 15 CFR). Controls change frequently, so treat the authorities' latest guidance and your export-control officer as authoritative; "not controlled (EAR99)" is not "no license." Listing is a regulatory category, not a judgment about any company or country.

China MOFCOM Lists (Control & Watch): 80-Entity Reference Sheet (through the 29 Jun 2026 wave)

All 80 entities on China MOFCOM's Control List and Watch List, in official / Chinese / English names. Being listed is a regulatory designation, not a judgment of the company — useful both for counterparty screening and for listed companies to understand where they stand. Based on primary sources (Announcements No. 11/12/27/28); as of 20 November 2026 there had been no additions or removals (checked through No. 56).

The BIS Affiliates Rule (50 Percent Rule) Readiness Checklist (2026)

A fill-in working checklist for trade compliance teams preparing for the BIS Affiliates Rule. Covers what the rule actually does (aggregation across owners and across lists, cascade/carry-forward, the rule of most restrictiveness, and why exactly 50% is in while below 50% is not automatically out), what is stayed and what is in effect now, where ownership data typically breaks, and a six-phase preparation list from scoping through governance. The stay was due to end on 9 November 2026; on that day BIS published a rule extending it to 10 January 2027 (91 FR 70789). The sheet is built to work whether the rule then returns, is stayed again, or is modified (as of 21 November 2026). Based on primary sources (90 FR 47201, 90 FR 50857, 91 FR 70789, 15 CFR, and China's Ministry of Commerce). Designation is a regulatory classification, not a judgement about a company; final determinations rest with your export-control officer and the authorities' current guidance.

See all materials

Related Knowledge Base

Export Control Guide

Solutions

Strengthen Export ComplianceStreamline compliance with complex export regulations

Talk with us about export-control operations

Share your screening, classification, or compliance workflow. We will map where TRAFEED can help—via our contact form (no cold booking).

Contact UsDownload Catalog

Related Articles

Does letting someone use a GPU over the network count as an export? The RASA bill, and whether Japan has the same gap

Does letting someone use a GPU over the network count as an export? The RASA bill, and whether Japan has the same gap

You can stop the chip from leaving the country, but you cannot stop someone from using it over a network connection. This piece traces where that difference comes from, working from the text of the EAR, BIS's own advisory opinions, and the Japanese Foreign Exchange and Foreign Trade Act. It covers what the RASA bill actually says, whether Japan has the same gap, and what to check in practice.

2026-08-21
The Ohkawara Kakohki Case: A Wrongful Prosecution Born from Export-Control 'Classification'

The Ohkawara Kakohki Case: A Wrongful Prosecution Born from Export-Control 'Classification'

If you work in export control, you will hear the name of this case sooner or later. The Ohkawara Kakohki case.

2026-07-11
"Is Your Technical Information Leaking?" Speaking at JX LIVE! 2026, Part One: Economic Security and Export Control in the Age of AI

"Is Your Technical Information Leaking?" Speaking at JX LIVE! 2026, Part One: Economic Security and Export Control in the Age of AI

On 28 July 2026 I spoke at JX LIVE! 2026, the Japan Association of New Economy's conference at TOKYO NODE in Toranomon Hills.

2026-08-01
The Asahi Kasei Arrest: Which Law Was Broken, and Where Export Controls Fit

The Asahi Kasei Arrest: Which Law Was Broken, and Where Export Controls Fit

On September 17, 2026, Aichi police arrested a former Asahi Kasei employee on suspicion of disclosing trade secrets on a latent curing agent used in semiconductor packaging to a Chinese company. Working from Asahi Kasei's own statement and Japanese press reports, this article lays out the timeline, explains which part of Japan's Unfair Competition Prevention Act the arrest rests on, why the Foreign Exchange and Foreign Trade Act and the Economic Security Promotion Act do not appear, and what to check in your own company today. Updated to include the reported indictment of October 27, 2026.

2026-09-18
Japan's Small-Amount Exception and No-Charge Exception in Export Control | When You Don't Need an Export License — Thresholds and Pitfalls [2026 Edition]

Japan's Small-Amount Exception and No-Charge Exception in Export Control | When You Don't Need an Export License — Thresholds and Pitfalls [2026 Edition]

Japan's small-amount exception (shougaku tokurei) and no-charge exception (mushou tokurei) explained for beginners - the 1 million yen and 50,000 yen thresholds, excluded item numbers and destinations, and the traps in practice, based on e-Gov, METI, and CISTEC primary sources.

2026-07-07
What Is Inward FDI Screening in Japan? A Plain-English Guide to FEFTA Prior Notification, the 1% Rule, and Core Sectors (2026)

What Is Inward FDI Screening in Japan? A Plain-English Guide to FEFTA Prior Notification, the 1% Rule, and Core Sectors (2026)

What Is Inward FDI Screening in Japan? A Plain-English Guide to FEFTA Prior Notification, the 1% Rule, and Core Sectors (2026).

2026-07-18